TNO and Janssen sign intention to develop new collaborations

Thema:
Efficient drug development
16 December 2020

Today, TNO Healthy Living and Janssen signed a letter of intent in which the parties declare their intention to explore multiple topics for the development of new collaborations.

The selected topics represent technological areas in which both parties foresee innovations that will contribute to breakthroughs in our understanding and precision treatment of disease, as well as health domains in which unmet needs require new approaches, and accelerating drug development. In addition, the parties are seeking collaboration on topics of mutual interest in which joint efforts may add up to more than the sum of the parts.

ondertekening-loi-tussen-tno-en-janssen-linkedin-jpg

Janssen - with its large R&D and production locations at Leiden Bio Science Park (the Netherlands) and Beerse (Belgium) - and TNO Healthy Living (which will have its main location at Leiden Bio Science Park as of Q1 2022) are both strong pillars in the research landscape of health and disease. In the ongoing COVID-19 pandemic, Janssen is at the forefront of vaccine development, while TNO has used its knowledge power on innovations to alleviate the burden of corona in various areas. Examples include introducing a new rapid test for COVID-19 and establishing a new laboratory for virus research.

The execution of this letter of intent marks the intention of Janssen and TNO to search for alignments in terms of the investments that both parties make in research and innovation. Peter Werkhoven, Chief Scientific Officer at TNO: “As the flywheel of innovation in our society, we operate in close collaboration with public and private partners to align our research agendas and accelerate societal and economic value creation. With high expectations, we are intensifying our collaboration with Janssen, a major player in fighting sickness with science.”

About Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, they’re creating a future where disease is a thing of the past. they’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. They focus on areas of medicine where they can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension.

More information can be found via www.janssen.com/netherlands or by following us on LinkedIn,Twitter, Facebookor Instagramfor our latest news.

Get inspired

27 resultaten, getoond 1 t/m 5

PPP uncovers new insights into MASLD development

Informatietype:
Insight
15 February 2024
Diagnostic service, pharmaceutical and nutrition partners came together in ProLiver to better understand organ-cross talk and test interventions for MASLD/MASH.

TNO research lays foundation for more reliable allergen information on food labels

Informatietype:
News
6 February 2024

Lifestyle disease models

Informatietype:
Article

Time setters: reduce long waits for new medication with AMS

Informatietype:
Insight
10 August 2023

Ancora Health develops personal diabetes plan with 360 methodology

Informatietype:
Insight
11 May 2023